title: Components of intrinsic drug resistance in the rat hepatoma.
abstract: A carcinogen-transformed rat hepatoma cell line (Reuber H-35) was utilized as a model system for investigation of the biochemical factors which may limit the effectiveness of chemotherapy in intrinsically resistant tumors such as hepatocellular carcinoma. Northern blotting demonstrated expression of mRNA coding for the P-170 membrane-glycoprotein associated with the multi-drug resistance phenotype, while Western blotting identified the P-170 glycoprotein in the hepatoma cell membrane. Consistent with these observations, tumor cell sensitivity to the vinca alkaloids, vincristine and vinblastine, to the anthracycline antibiotics, Adriamycin and daunorubicin, and to the demethylepipodophyllotoxin derivative, VM-26, was enhanced by continuous incubation in the presence of the calcium channel antagonist, verapamil. Verapamil produced a minimal change in cell sensitivity to the demethylepipodophyllotoxin derivative, VP-16, and to the aminoacridine, m-AMSA. Relatively high detoxification potential via the glutathione metabolic pathway was also observed in the hepatoma cell. The capacity of topoisomerase II in nuclear extracts from the hepatoma cell to mediate cleavable complex formation stimulated by VM-26, VP-16 and m-AMSA appeared to be at least comparable to, if not greater than that from drug-sensitive HL-60 cells, suggesting that drug resistance may not occur at the level of this enzyme. Consistent with findings in a number of tumor cell lines resistant to antineoplastic drugs, the antiproliferative activity of the topoisomerase II inhibitors VM-26, VP-16 and m-AMSA appeared to be dissociable from the induction of DNA strand breaks, suggesting that such lesions in DNA may fail to fully account for the antiproliferative activity of these agents in the hepatoma cell.
authors.affiliation: Department of Pharmacology, Medical College of Virginia, Richmond 23298.
authors.forename: A L
authors.initials: AL
authors.lastname: Ellis
authors.forename: C E
authors.initials: CE
authors.lastname: Munger
authors.forename: R T
authors.initials: RT
authors.lastname: Bunch
authors.forename: K E
authors.initials: KE
authors.lastname: Woods
authors.forename: J K
authors.initials: JK
authors.lastname: Randolph
authors.forename: L
authors.initials: L
authors.lastname: Boise
authors.forename: P S
authors.initials: PS
authors.lastname: Swerdlow
authors.forename: L A
authors.initials: LA
authors.lastname: Zwelling
authors.forename: M
authors.initials: M
authors.lastname: Hinds
authors.forename: S
authors.initials: S
authors.lastname: Yanovich
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D015152:Blotting, Northern; D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D002458:Cell Fractionation; D002460:Cell Line / Q000187:drug effects; D004249:DNA Damage; D004351:Drug Resistance / Q000235:genetics*; D005978:Glutathione / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000201:enzymology / Q000235:genetics*; D008562:Membrane Glycoproteins / Q000378:metabolism; D010641:Phenotype; D051381:Rats; D059005:Topoisomerase II Inhibitors; D014700:Verapamil / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D008562:Membrane Glycoproteins; D059005:Topoisomerase II Inhibitors; D014700:Verapamil; D005978:Glutathione